Detalhe da pesquisa
1.
Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain.
Glob Reg Health Technol Assess
; 9: 82-90, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36628311
2.
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program.
Oncotarget
; 13: 812-827, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35720977
3.
Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib.
Lung Cancer Manag
; 9(1): LMT28, 2020 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32256712
4.
Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer.
Anticancer Res
; 39(3): 1317-1328, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842164
5.
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer.
Clinicoecon Outcomes Res
; 9: 31-38, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28115857